

Chun Hei Antonio Cheung

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9183146/publications.pdf>

Version: 2024-02-01

56
papers

6,386
citations

236612

25
h-index

205818

48
g-index

60
all docs

60
docs citations

60
times ranked

15779
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | The "Dark Side" of autophagy on the maintenance of genome stability: Does it really exist during excessive activation?. <i>Journal of Cellular Physiology</i> , 2022, 237, 178-188. | 2.0 | 3 |
| 2 | FTY720 in resistant human epidermal growth factor receptor 2-positive breast cancer. <i>Scientific Reports</i> , 2022, 12, 241. | 1.6 | 5 |
| 3 | Early A β 242 Exposure Causes Learning Impairment in Later Life. , 2022, 13, 868. | | 0 |
| 4 | Survivin - caspase protein-protein interaction: Experimental evidence and computational investigations to decipher the hotspot residues for drug targeting. <i>Journal of Molecular Structure</i> , 2021, 1229, 129619. | 1.8 | 8 |
| 5 | YM155 and BIRC5 downregulation induce genomic instability via autophagy-mediated ROS production and inhibition in DNA repair. <i>Pharmacological Research</i> , 2021, 166, 105474. | 3.1 | 13 |
| 6 | Rac1 and Akt Exhibit Distinct Roles in Mediating A β 2-Induced Memory Damage and Learning Impairment. <i>Molecular Neurobiology</i> , 2021, 58, 5224-5238. | 1.9 | 5 |
| 7 | An Updated Review of Smac Mimetics, LCL161, Birinapant, and GDC-0152 in Cancer Treatment. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 335. | 1.3 | 17 |
| 8 | BIRC5/Survivin is a novel ATG12-ATG5 conjugate interactor and an autophagy-induced DNA damage suppressor in human cancer and mouse embryonic fibroblast cells. <i>Autophagy</i> , 2020, 16, 1296-1313. | 4.3 | 78 |
| 9 | The SMAC mimetic LCL161 is a direct ABCB1/MDR1-ATPase activity modulator and BIRC5/Survivin expression down-regulator in cancer cells. <i>Toxicology and Applied Pharmacology</i> , 2020, 401, 115080. | 1.3 | 12 |
| 10 | Tamoxifen Rechallenge Decreases Metastatic Potential but Increases Cell Viability and Clonogenicity in a Tamoxifen-Mediated Cytotoxicity-Resistant Subline of Human Breast MCF7 Cancer Cells. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 485. | 1.8 | 5 |
| 11 | Anti-apoptotic proteins in the autophagic world: an update on functions of XIAP, Survivin, and BRUCE. <i>Journal of Biomedical Science</i> , 2020, 27, 31. | 2.6 | 57 |
| 12 | Modulating tumor immune microenvironment by the STK11/LKB1 signaling in breast cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, e15185-e15185. | 0.8 | 0 |
| 13 | Abstract 2487: Mutation of the STK11 gene predicts recurrence of breast cancer. , 2020, , . | | 0 |
| 14 | Mutation of the PTCH1 gene predicts recurrence of breast cancer. <i>Scientific Reports</i> , 2019, 9, 16359. | 1.6 | 34 |
| 15 | Aging-induced Akt activation involves in aging-related pathologies and A β 2-induced toxicity. <i>Aging Cell</i> , 2019, 18, e12989. | 3.0 | 26 |
| 16 | Cloning, expression, and purification of the recombinant pro-apoptotic dominant-negative survivin T34A-C84A protein in <i>Escherichia coli</i> . <i>Protein Expression and Purification</i> , 2019, 160, 73-83. | 0.6 | 7 |
| 17 | Dysfunction of different cellular degradation pathways contributes to specific A β 2-induced pathologies. <i>FASEB Journal</i> , 2018, 32, 1375-1387. | 0.2 | 12 |
| 18 | Topical Ophthalmic Formulation of Trichostatin A and SurR9-C84A for Quick Recovery Post-alkali Burn of Corneal Haze. <i>Frontiers in Pharmacology</i> , 2017, 8, 223. | 1.6 | 3 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | HDAC2 and HDAC5 Up-Regulations Modulate Survivin and miR-125a-5p Expressions and Promote Hormone Therapy Resistance in Estrogen Receptor Positive Breast Cancer Cells. <i>Frontiers in Pharmacology</i> , 2017, 8, 902. | 1.6 | 29 |
| 20 | Abstract 3303: Survivin negatively-regulates autophagy through interference with the formation of Atg5-Atg12-Atg16L complex in breast cancer cells. , 2017, . | | 0 |
| 21 | Delivery of a survivin promoter-driven antisense survivin-expressing plasmid DNA as a cancer therapeutic: a proof-of-concept study. <i>OncoTargets and Therapy</i> , 2016, 9, 2601. | 1.0 | 8 |
| 22 | Inhibition of HDAC3- and HDAC6-Promoted Survivin Expression Plays an Important Role in SAHA-Induced Autophagy and Viability Reduction in Breast Cancer Cells. <i>Frontiers in Pharmacology</i> , 2016, 7, 81. | 1.6 | 53 |
| 23 | E-Cadherin Aptamer-Conjugated Delivery of Doxorubicin for Targeted Inhibition of Prostate Cancer Cells. <i>Australian Journal of Chemistry</i> , 2016, 69, 1108. | 0.5 | 6 |
| 24 | Disruption of proteinâ€“protein interactions: hot spot detection, structure-based virtual screening and in vitro testing for the anti-cancer drug target â€“ survivin. <i>RSC Advances</i> , 2016, 6, 31947-31959. | 1.7 | 35 |
| 25 | Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222. | 4.3 | 4,701 |
| 26 | Competitive inhibition of survivin using a cell-permeable recombinant protein induces cancer-specific apoptosis in colon cancer model. <i>International Journal of Nanomedicine</i> , 2015, 10, 1019. | 3.3 | 10 |
| 27 | <i>O</i> ⁶ -methylguanine DNA methyltransferase repairs platinum-DNA adducts following cisplatin treatment and predicts prognoses of nasopharyngeal carcinoma. <i>International Journal of Cancer</i> , 2015, 137, 1291-1305. | 2.3 | 30 |
| 28 | Locked nucleic acid modified bi-specific aptamer-targeted nanoparticles carrying survivin antagonist towards effective colon cancer therapy. <i>RSC Advances</i> , 2015, 5, 29008-29016. | 1.7 | 18 |
| 29 | <i>YM155</i> downâ€“regulates survivin and <i>XIAP</i> , modulates autophagy and induces autophagyâ€“dependent <i>DNA</i> damage in breast cancer cells. <i>British Journal of Pharmacology</i> , 2015, 172, 214-234. | 2.7 | 79 |
| 30 | Clinical aspects for survivin: a crucial molecule for targeting drug-resistant cancers. <i>Drug Discovery Today</i> , 2015, 20, 578-587. | 3.2 | 68 |
| 31 | Aurora kinase inhibitor patents and agents in clinical testing: an update (2011 â€“ 2013). <i>Expert Opinion on Therapeutic Patents</i> , 2014, 24, 1021-1038. | 2.4 | 57 |
| 32 | The Inducible Nitric-oxide Synthase (iNOS)/Src Axis Mediates Toll-like Receptor 3 Tyrosine 759 Phosphorylation and Enhances Its Signal Transduction, Leading to Interferon- β Synthesis in Macrophages. <i>Journal of Biological Chemistry</i> , 2014, 289, 9208-9220. | 1.6 | 16 |
| 33 | Caspase-Independent Apoptosis. , 2014, , 823-824. | | 0 |
| 34 | Autophagy induced by cathepsin S inhibition induces early ROS production, oxidative DNA damage, and cell death via xanthine oxidase. <i>Free Radical Biology and Medicine</i> , 2013, 65, 1473-1486. | 1.3 | 57 |
| 35 | Treat cancers by targeting survivin: Just a dream or future reality?. <i>Cancer Treatment Reviews</i> , 2013, 39, 802-811. | 3.4 | 129 |
| 36 | Survivin – biology and potential as a therapeutic target in oncology. <i>OncoTargets and Therapy</i> , 2013, 6, 1453. | 1.0 | 128 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Abstract 3452: YM155 induces autophagy-dependent cell death in Tamoxifen-resistant breast cancer cells.. , 2013, , . | | 0 |
| 38 | Cancer Targeted Nanoparticles Specifically Induce Apoptosis in Cancer Cells and Spare Normal Cells. Australian Journal of Chemistry, 2012, 65, 5. | 0.5 | 18 |
| 39 | Targeting cathepsin S induces tumor cell autophagy via the EGFR-ERK signaling pathway. Cancer Letters, 2012, 317, 89-98. | 3.2 | 66 |
| 40 | Modulating the interaction of CXCR4 and CXCL12 by low-molecular-weight heparin inhibits hepatic metastasis of colon cancer. Investigational New Drugs, 2012, 30, 508-517. | 1.2 | 41 |
| 41 | Enhancement of non-homologous end joining DNA repair capacity confers cancer cells resistance to the novel selenophene compound, D-501036. Cancer Letters, 2011, 309, 110-118. | 3.2 | 7 |
| 42 | Aurora kinase inhibitor patents and agents in clinical testing: an update (2009 - 10). Expert Opinion on Therapeutic Patents, 2011, 21, 857-884. | 2.4 | 38 |
| 43 | Investigations of survivin: the past, present and future. Frontiers in Bioscience - Landmark, 2011, 16, 952. | 3.0 | 52 |
| 44 | BPR1K653, a Novel Aurora Kinase Inhibitor, Exhibits Potent Anti-Proliferative Activity in MDR1 (P-gp170)-Mediated Multidrug-Resistant Cancer Cells. PLoS ONE, 2011, 6, e23485. | 1.1 | 16 |
| 45 | Proliferative and protective effects of SurR9-C84A on differentiated neural cells. Journal of Neuroimmunology, 2010, 227, 120-132. | 1.1 | 27 |
| 46 | Chamaecypanone C, a novel skeleton microtubule inhibitor, with anticancer activity by trigger caspase 8-Fas/FasL dependent apoptotic pathway in human cancer cells. Biochemical Pharmacology, 2010, 79, 1261-1271. | 2.0 | 27 |
| 47 | A cell-permeable dominant-negative survivin protein induces apoptosis and sensitizes prostate cancer cells to TNF- α therapy. Cancer Cell International, 2010, 10, 36. | 1.8 | 48 |
| 48 | Cancer Cells Acquire Mitotic Drug Resistance Properties Through Beta I-Tubulin Mutations and Alterations in the Expression of Beta-Tubulin Isoforms. PLoS ONE, 2010, 5, e12564. | 1.1 | 41 |
| 49 | Recent Advances in Anti-Survivin Treatments for Cancer. Current Medicinal Chemistry, 2010, 17, 1509-1515. | 1.2 | 65 |
| 50 | Targeting Hsp90 with small molecule inhibitors induces the over-expression of the anti-apoptotic molecule, survivin, in human A549, HONE-1 and HT-29 cancer cells. Molecular Cancer, 2010, 9, 77. | 7.9 | 47 |
| 51 | Aurora kinase inhibitors in preclinical and clinical testing. Expert Opinion on Investigational Drugs, 2009, 18, 379-398. | 1.9 | 93 |
| 52 | Advances in Aurora kinase inhibitor patents. Expert Opinion on Therapeutic Patents, 2009, 19, 321-356. | 2.4 | 24 |
| 53 | Survivin counteracts the therapeutic effect of microtubule de-stabilizers by stabilizing tubulin polymers. Molecular Cancer, 2009, 8, 43. | 7.9 | 57 |
| 54 | Down-regulation of Survivin enhances sensitivity to BPR0L075 in human cancer cells via caspase-independent mechanisms. Nature Precedings, 2008, , . | 0.1 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Challenges in Treating Estrogen Receptor-Positive Breast Cancer. , 0, , . | | 5 |
| 56 | Introduction to this special issue - Autophagy and Cancer: current biology and drug development. Journal of Cancer Metastasis and Treatment, 0, 2019, . | 0.5 | 0 |